Home » ASH 2013 Multiple Myeloma Gateway

ASH 2013 Multiple Myeloma Gateway

The Myeloma Beacon is your one-stop source for information about the myeloma-related research being presented at the 2013 American Society of Hematology meeting in New Orleans.

This gateway provides a convenient launchpad for accessing all the Beacon's ASH 2013-related resources.

Information in the gateway will be updated regularly as the Beacon publishes additional articles about the research presented at ASH, and as other changes are made to the Beacon's ASH-related content.

Gateway Index

  1. Abstracts
  2. Meeting sessions
  3. Beacon articles related to the meeting
  4. Abstracts by topic

Abstracts

All Abstracts All myeloma-related abstracts from the ASH 2013 meeting available at The Beacon.
Abstracts With Files All meeting abstracts at The Beacon that have links to files with relevant slide decks or posters. (Files can be viewed by clicking on the hyperlinks in these abstracts that are labeled either "Slide Deck" or "Full Poster.")

The ASH abstracts at The Beacon can be searched from the search box that appears above each abstract and above all lists of abstracts.  Please note that meeting abstracts will not appear in the results of searches carried out from the Beacon's general search box located in the Beacon's top menu bar.

Meeting Sessions

The table below lists the sessions at the 2013 ASH meeting that will have at least one myeloma-related presentation. The sessions are sorted by date and time.

The hyperlink included with each session name links to a list of all myeloma-related presentations during that session.  The dates (Sat-Tue) are December 7-10, respectively.  The "# of abstracts" is the number of myeloma-related presentations scheduled to be made during the session.

*The time listed for an oral session is the scheduled time of the first myeloma-related presentation during the session.

Day Time* Session
Type		 Session Name Location # of
Abstracts
Sat 9:30a Oral Education Session
(3 presentations; no abstracts available)		 Theater AB 3
Sat 2:30p Oral Scientific Program 293-296 3
Sat 5:30p Poster 322. Disorders of Coagulation or Fibrinolysis: Poster I Hall E 1
Sat 5:30p Poster 601. Chromosomal Rearrangements and DNA Repair: Poster I Hall E 2
Sat 5:30p Poster 613. Acute Myeloid Leukemia: Pathophysiology & Clinical Studies: Poster I Hall E 1
Sat 5:30p Poster 802. Chemical Biology and Experimental Therapeutics: Poster I Hall E 2
Sat 5:30p Poster 901. Health Services and Outcomes Research: Poster I Hall E 8
Sat 5:30p Poster 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I Hall G 70
Sat 5:30p Poster 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I Hall G 14
Sat 5:30p Poster 653. Myeloma: Therapy, excluding Transplantation: Poster I Hall G 59
Sat 5:30p Poster 702. Experimental Transplantation: Immune Function, GVHD and Graft-versus-Tumor Effects: Poster I Hall G 1
Sat 5:30p Poster 711. Cell Collection and Processing: Poster I Hall G 2
Sat 5:30p Poster 723. Clinical Allogeneic and Autologous Transplantation - Late Complications and Approaches to Disease Recurrence: Poster I Hall G 1
Sat 5:30p Poster 731. Clinical Allogeneic and Autologous Transplantation - Results: Poster I Hall G 14
Sun 7:30a Oral Scientific Program 293-296 3
Sun 9:30a Oral Education Session
(3 presentations; no abstracts available)		 Theater AB 3
Sun 2:55p Oral Plenary Session Hall F 1
Sun 5:15p Oral 203. Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and Other Infections: NK Cell Biology 395-396 1
Sun 5:00p Oral 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Predictive Markers of Myeloma Biology 388-390 6
Sun 5:00p Oral 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Signaling and Microenvironment 391-392 6
Sun 5:00p Oral 703. Adoptive Immunotherapy: Novel T cell Therapies 393-394 3
Sun 5:00p Oral 723. Clinical Allogeneic and Autologous Transplantation - Late Complications and Approaches to Disease Recurrence: Relapse after Transplantation - Novel Strategies R06-R07 2
Sun 5:15p Oral 731. Clinical Allogeneic and Autologous Transplantation - Results: Haploidentical and Umbilical Cord Blood Transplantation 208-210 1
Sun 6:30p Poster 603. Oncogenes and Tumor Suppressors: Poster II Hall E 1
Sun 6:30p Poster 604. Molecular Pharmacology, Drug Resistance: Poster II Hall E 1
Sun 6:30p Poster 802. Chemical Biology and Experimental Therapeutics: Poster II Hall E
Sun 6:30p Poster 901. Health Services and Outcomes Research: Poster II Hall E 9
Sun 6:30p Poster 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II Hall G 70
Sun 6:30p Poster 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II Hall G 15
Sun 6:30p Poster 653. Myeloma: Therapy, excluding Transplantation: Poster II Hall G 57
Sun 6:30p Poster 702. Experimental Transplantation: Immune Function, GVHD and Graft-versus-Tumor Effects: Poster II Hall G 1
Sun 6:30p Poster 711. Cell Collection and Processing: Poster II Hall G 1
Sun 6:30p Poster 723. Clinical Allogeneic and Autologous Transplantation - Late Complications and Approaches to Disease Recurrence: Poster II Hall G 3
Sun 6:30p Poster 731. Clinical Allogeneic and Autologous Transplantation - Results: Poster II Hall G 21
Mon 7:15a Oral 611. Leukemias: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Genomic Alterations in Acute Lymphoblastic Leukemia--Implications for Pathogenesis, Prognosis and Therapy 291-292 1
Mon 7:00a Oral 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Novel Biological Targets 388-390 5
Mon 7:00a Oral 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Drug Resistance 391-392 6
Mon 7:00a Oral 653. Myeloma: Therapy, excluding Transplantation: Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma 393-394 5
Mon 10:30a Oral 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Clonal Evolution and Genomic Heterogeneity in Myeloma 388-390 6
Mon 10:30a Oral 653. Myeloma: Therapy, excluding Transplantation I 393-394 6
Mon 10:45a Oral 731. Clinical Allogeneic and Autologous Transplantation - Results: Autologous Transplantation for Lymphoma, Myeloma and APL 208-210 2
Mon 2:45p Oral 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Genomics 388-390 6
Mon 3:00p Oral 624. Lymphoma: Therapy with Biological Agents, Excluding Pre-Clinical Models: Immunotherapy for Indolent Lymphomas Ballroom AB 1
Mon 2:45p Oral 653. Myeloma: Therapy, excluding Transplantation: Treatment Options for Newly Diagnosed Multiple Myeloma Patients 393-394 6
Mon 3:00p Oral 731. Clinical Allogeneic and Autologous Transplantation - Results: Optimizing Outcomes After Transplantation - Selecting Patients, Donor and Transplant Strategies 208-210 1
Mon 5:30p Oral 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Epigenetics of Hematopoiesis and Leukemia 395-396 1
Mon 4:30p Oral 604. Molecular Pharmacology, Drug Resistance: Environmental Implications in Leukemia Therapy and Molecular Mechanisms of Drug Resistance and Novel Biomarkers in Hematologic Malignances 275-277 2
Mon 4:30p Oral 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Bone Marrow Microenvironment and Myeloma 388-390 6
Mon 4:30p Oral 653. Myeloma: Therapy, excluding Transplantation II 393-394 6
Mon 5:00p Oral 901. Health Services and Outcomes Research: Malignant Hematology and Stem Cell Transplantation 391-392 1
Mon 5:00p Oral 611. Leukemias: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis I 291-292 1
Mon 7:15p Oral 611. Leukemias: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis I 291-292 1
Mon 6:15p Oral 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Microenvironment 388-390 6
Mon 6:30p Oral 653. Myeloma: Therapy, excluding Transplantation: Advances in Multiple Myeloma and Plasma Cell Leukemia 393-394 5
Mon 6:15p Oral 731. Clinical Allogeneic and Autologous Transplantation - Results: Evidence-based Decision Making II - Transplantation for Lymphoma and Plasma Cell Disorders 208-210 4
Mon 6:00p Poster 203. Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and Other Infections: Poster III Hall E 2
Mon 6:00p Poster 331. Pathophysiology of Thrombosis: Poster III Hall E 1
Mon 6:00p Poster 601. Chromosomal Rearrangements and DNA Repair: Poster III Hall E 1
Mon 6:00p Poster 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster III Hall E 2
Mon 6:00p Poster 604. Molecular Pharmacology, Drug Resistance: Poster III Hall E 4
Mon 6:00p Poster 661. Malignant Stem and Progenitor Cells: Poster III Hall E 1
Mon 6:00p Poster 801. Gene Therapy and Transfer: Poster III Hall E 1
Mon 6:00p Poster 802. Chemical Biology and Experimental Therapeutics: Poster III Hall E 4
Mon 6:00p Poster 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster III Hall G 1
Mon 6:00p Poster 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster III Hall G 27
Mon 6:00p Poster 703. Adoptive Immunotherapy: Poster III Hall G 1
Mon 6:00p Poster 711. Cell Collection and Processing: Poster III Hall G 3
Mon 6:00p Poster 722. Clinical Allogeneic Transplantation - Acute and Chronic GVHD, Immune Reconstitution: Poster III Hall G 1
Mon 6:00p Poster 723. Clinical Allogeneic and Autologous Transplantation - Late Complications and Approaches to Disease Recurrence: Poster III Hall G 1
Tue 8:15a Oral 601. Chromosomal Rearrangements and DNA Repair 220-222 1
Tue 7:45a Oral 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Standard Therapies and Novel Targets For All Ages Ballroom C 1
Tue 7:30a Oral 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Novel Drugs 295-296 6
Tue 8:00a Oral 703. Adoptive Immunotherapy: Optimizing Cellular Therapy 393-394 1
Tue 8:15a Oral 711. Cell Collection and Processing II R02-R03 3
Tue 7:45a Oral 723. Clinical Allogeneic and Autologous Transplantation - Late Complications and Approaches to Disease Recurrence: Late Complications R06-R07 1
Tue 7:45a Oral 731. Clinical Allogeneic and Autologous Transplantation - Results: Allogeneic Transplantation 208-210 1
Tue 8:30a Oral 802. Chemical Biology and Experimental Therapeutics: New Experimental Therapeutic Approaches to Benign and Malignant Hematology R04-R05 1

 
Beacon Articles Related To The Meeting

Post-Meeting Reports

Meeting Updates

Meeting Previews

Abstracts By Topic

The Beacon editorial team has "tagged" many of the ASH abstracts to make it easy to view abstracts about specific myeloma-related topics.  The following is a list of some of the popular categories defined by the tags (or combinations of the tags)

General Topic Specific Topics
Potential new therapies New treatments under development
Clinical trial results for new treatments
Preclinical research about new treatments
Therapies already being marketed Revlimid (lenalidomide)
Velcade (bortezomib)
Kyprolis (carfilzomib)
Pomalyst (pomalidomide, Imnovid)
Thalidomide (Thalomid)
Cyclophosphamide (Cytoxan)
Melphalan (Alkeran)
Prednisone
Doxorubicin (Adriamycin)
Treanda (bendamustine)
Clarithromycin (Biaxin)
Doxil (doxorubicin liposomal)
Classes of therapies
(includes abstracts about single agents in the specified classes and abstracts about the class as a whole)		 Immunomodulatory agents
Proteasome inhibitors
HDAC inhibitors
Monoclonal antibodies
Transplantation Transplantation (any type)
Autologous (own stem cell) transplantation
Allogeneic (donor stem cell) transplantation
Stem cell mobilization
Other therapy-related topics Maintenance therapy
Consolidation therapy
Bisphosphonate treatment
Secondary cancer
Related conditions and disease characteristics Smoldering myeloma
MGUS (monoclonal gammopathy of undetermined significance)
Plasma cell leukemia
Amyloidosis
Extramedullary disease
Other topics Chromosomal abnormalities
Minimal residual disease
Gene expression profiling
Imaging
Treatment biomarkers
Bone disease
Kidney disease and/or failure
Survival

4 Comments »

  • Pete said:

    What is the status of Elotuzumab? I don't see any abstracts discussing it.

    # 8 December 2013 at 6:24 pm
  • Myeloma Beacon Staff (author) said:

    Hi Pete - We don't think anything is amiss with elotuzumab. There just aren't any presentations about it this year at ASH.

    However, we're looking into it, and we'll let you know what we find out.

    Thanks for the question.

    # 9 December 2013 at 1:32 am
  • Pete said:

    To Myeloma Beacon Staff:

    Thanks for checking on that.

    On a different topic: daratumumab had been designated by the FDA with 'fast track status' back in April 2013:

    http://www.myelomabeacon.com/news/2013/04/08/beacon-newsflashes-april-8-2013/

    What is your sense, based on the ASH 2013 abstracts, that daratumumab will be approved in the next 6-9 month? I understand that your reply (if any) would be highly speculative. But you folks might have a better feel for this than a layperson like me.

    Thank you.

    Pete

    # 9 December 2013 at 9:56 am
  • indira veerisettyMD said:

    Hi how can I order abstracts on the Myeloma presentations

    # 10 December 2013 at 9:12 am